Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium
Status:
Terminated
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on
Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range
of ≥40 and ≤70 mL/min/1.73m2.